Patient characteristics
. | Suspected . | Confirmed . | Transformed at time of diagnosis . | No transformation . |
---|---|---|---|---|
n = 232 . | n = 147 . | n = 47 . | n= 2273 . | |
Extranodal sites | ||||
≤1 | 171 (74%) | 100 (68%) | 39 (83%) | 1801 (79%) |
>1 | 52 (22%) | 43 (29%) | 4 (9%) | 394 (17%) |
Not done/missing | 9 (4%) | 4 (3%) | 4 (9%) | 78 (3%) |
Nodal sites | ||||
≤4 | 131 (56%) | 86 (59%) | 31 (66%) | 1463 (64%) |
>4 | 88 (38%) | 58 (39%) | 15 (32%) | 718 (32%) |
Not done/missing | 13 (6%) | 3 (2%) | 1 (2%) | 92 (4%) |
Grade | ||||
I/II | 170 (73%) | 103 (70%) | 9 (19%) | 1632 (72%) |
III | 37 (16%) | 23 (16%) | 7 (15%) | 428 (19%) |
Unknown/missing | 25 (11%) | 21 (14%) | 31 (66%) | 213 (9%) |
ECOG PS | ||||
0-1 | 126 (54%) | 89 (61%) | 33 (70%) | 1525 (67%) |
≥2 | 11 (5%) | 6 (4%) | 2 (4%) | 70 (3%) |
Not done/missing | 95 (41%) | 52 (35%) | 12 (26%) | 678 (30%) |
Hb | ||||
<12 g/dL | 49 (21%) | 37 (25%) | 10 (21%) | 434 (19%) |
≥12 g/dL | 162 (70%) | 101 (69%) | 37 (79%) | 1692 (74%) |
Not done/missing | 21 (9%) | 9 (6%) | 0 | 147 (6%) |
LDH | ||||
Normal | 130 (56%) | 72 (49%) | 25 (53%) | 1393 (61%) |
>ULN | 37 (16%) | 31 (21%) | 12 (26%) | 358 (16%) |
Not done/missing | 65 (28%) | 44 (30%) | 10 (21%) | 522 (23%) |
Stage | ||||
I/II | 66 (28%) | 35 (24%) | 14 (30%) | 761 (33%) |
III/IV | 163 (70%) | 111 (76%) | 33 (70%) | 1489 (66%) |
Not done/missing | 3 (1%) | 1 (1%) | 0 | 23 (1%) |
B symptoms | ||||
No | 162 (70%) | 103 (70%) | 33 (70%) | 1716 (75%) |
Yes | 70 (30%) | 44 (30%) | 14 (30%) | 557 (25%) |
Age | ||||
<60 | 91 (39%) | 62 (42%) | 18 (38%) | 1028 (45%) |
60-69 | 55 (24%) | 46 (31%) | 14 (30%) | 582 (26%) |
70-79 | 55 (24%) | 33 (22%) | 6 (13%) | 448 (20%) |
80+ | 31 (13%) | 6 (4%) | 9 (19%) | 215 (9%) |
FLIPI | ||||
0-1 | 48 (21%) | 23 (16%) | 12 (26%) | 679 (30%) |
2 | 55 (24%) | 38 (26%) | 10 (21%) | 549 (24%) |
3-5 | 73 (31%) | 52 (35%) | 17 (36%) | 602 (26%) |
Missing | 56 (24%) | 34 (23%) | 8 (17%) | 443 (19%) |
. | Suspected . | Confirmed . | Transformed at time of diagnosis . | No transformation . |
---|---|---|---|---|
n = 232 . | n = 147 . | n = 47 . | n= 2273 . | |
Extranodal sites | ||||
≤1 | 171 (74%) | 100 (68%) | 39 (83%) | 1801 (79%) |
>1 | 52 (22%) | 43 (29%) | 4 (9%) | 394 (17%) |
Not done/missing | 9 (4%) | 4 (3%) | 4 (9%) | 78 (3%) |
Nodal sites | ||||
≤4 | 131 (56%) | 86 (59%) | 31 (66%) | 1463 (64%) |
>4 | 88 (38%) | 58 (39%) | 15 (32%) | 718 (32%) |
Not done/missing | 13 (6%) | 3 (2%) | 1 (2%) | 92 (4%) |
Grade | ||||
I/II | 170 (73%) | 103 (70%) | 9 (19%) | 1632 (72%) |
III | 37 (16%) | 23 (16%) | 7 (15%) | 428 (19%) |
Unknown/missing | 25 (11%) | 21 (14%) | 31 (66%) | 213 (9%) |
ECOG PS | ||||
0-1 | 126 (54%) | 89 (61%) | 33 (70%) | 1525 (67%) |
≥2 | 11 (5%) | 6 (4%) | 2 (4%) | 70 (3%) |
Not done/missing | 95 (41%) | 52 (35%) | 12 (26%) | 678 (30%) |
Hb | ||||
<12 g/dL | 49 (21%) | 37 (25%) | 10 (21%) | 434 (19%) |
≥12 g/dL | 162 (70%) | 101 (69%) | 37 (79%) | 1692 (74%) |
Not done/missing | 21 (9%) | 9 (6%) | 0 | 147 (6%) |
LDH | ||||
Normal | 130 (56%) | 72 (49%) | 25 (53%) | 1393 (61%) |
>ULN | 37 (16%) | 31 (21%) | 12 (26%) | 358 (16%) |
Not done/missing | 65 (28%) | 44 (30%) | 10 (21%) | 522 (23%) |
Stage | ||||
I/II | 66 (28%) | 35 (24%) | 14 (30%) | 761 (33%) |
III/IV | 163 (70%) | 111 (76%) | 33 (70%) | 1489 (66%) |
Not done/missing | 3 (1%) | 1 (1%) | 0 | 23 (1%) |
B symptoms | ||||
No | 162 (70%) | 103 (70%) | 33 (70%) | 1716 (75%) |
Yes | 70 (30%) | 44 (30%) | 14 (30%) | 557 (25%) |
Age | ||||
<60 | 91 (39%) | 62 (42%) | 18 (38%) | 1028 (45%) |
60-69 | 55 (24%) | 46 (31%) | 14 (30%) | 582 (26%) |
70-79 | 55 (24%) | 33 (22%) | 6 (13%) | 448 (20%) |
80+ | 31 (13%) | 6 (4%) | 9 (19%) | 215 (9%) |
FLIPI | ||||
0-1 | 48 (21%) | 23 (16%) | 12 (26%) | 679 (30%) |
2 | 55 (24%) | 38 (26%) | 10 (21%) | 549 (24%) |
3-5 | 73 (31%) | 52 (35%) | 17 (36%) | 602 (26%) |
Missing | 56 (24%) | 34 (23%) | 8 (17%) | 443 (19%) |
Hb, hemoglobin; LDH, lactate dehydrogenase; PS, performance status; ULN, upper limit of normal.